LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Atidarymo kaina

29.55 0.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.99

Max

29.89

Pagrindiniai rodikliai
By Trading Economics
Pajamos	43M 13M
Pardavimai	29M 107M
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	12.139
Darbuotojai	524
EBITDA	16M 8.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+125.91% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	17M 1.5B
Ankstesnė atidarymo kaina	29.52
Ankstesnė uždarymo kaina	29.55

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-26 16:52; UTC

Svarbiausios naujienos

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q Rev $1.76B >SQM

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q EPS $1.28 >SQM

2026-05-26 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q EPS $11.61 >WEBC

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q Sales $179.6M >WEBC

2026-05-26 21:48; UTC

Rinkos pokalbiai

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

2026-05-26 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2026-05-26 20:58; UTC

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

2026-05-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 19:22; UTC

Rinkos pokalbiai

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

2026-05-26 19:17; UTC

Rinkos pokalbiai

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

2026-05-26 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

2026-05-26 18:03; UTC

Rinkos pokalbiai

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

2026-05-26 17:42; UTC

Rinkos pokalbiai

Grains Await Fresh Trading Catalyst -- Market Talk

2026-05-26 17:33; UTC

Rinkos pokalbiai

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

2026-05-26 17:21; UTC

Rinkos pokalbiai

Canada Faces a Labor Market Squeeze -- Market Talk

2026-05-26 16:52; UTC

Rinkos pokalbiai

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

2026-05-26 16:43; UTC

Rinkos pokalbiai

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

2026-05-26 16:24; UTC

Rinkos pokalbiai

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

2026-05-26 16:21; UTC

Rinkos pokalbiai

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-05-26 16:16; UTC

Rinkos pokalbiai

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

2026-05-26 16:01; UTC

Rinkos pokalbiai

Bitcoin Lower as Stress Builds for Holders -- Market Talk

2026-05-26 15:21; UTC

Rinkos pokalbiai

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

125.91% į viršų

12 mėnesių prognozė

Vidutinis 65.13 USD 125.91%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.